Literature DB >> 10839869

Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children.

P Vajro1, A Franzese, G Valerio, M P Iannucci, N Aragione.   

Abstract

OBJECTIVE: To determine whether ursodeoxycholic acid (UDCA) is effective for treatment of obesity-related liver abnormalities in children. STUDY
DESIGN: Thirty-one children (21 bboys; mean age, 8.7 years) had obesity-related persistent elevation of aminotransferase levels, which was associated with ultrasonographic images of bright liver in 27. A preliminary interview determined which patients were (n = 18) or were not (n = 13) likely to comply with a balanced low-calorie diet. Four subgroups emerged: patients who followed the diet (n = 11), patients treated with UDCA (10 mg/kg/d) given alone (n = 7) or added to the diet (n = 7), and untreated control patients (n = 6).
RESULTS: Diet alone determined weight loss and resolved biochemical liver abnormalities in all patients. Addition of UDCA to the diet was no more efficacious than weight loss alone. UDCA alone was ineffective for the treatment of liver abnormalities in all cases, and results did not differ from those observed in the untreated control group. Improvement of ultrasonographic abnormalities was observed in patients who lost weight, irrespective of UDCA administration.
CONCLUSIONS: UDCA is not effective for the treatment of obesity-related liver abnormalities in children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10839869

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  23 in total

1.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

2.  Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

4.  Nonalcoholic fatty liver disease.

Authors:  Diana Mager; Eve Roberts
Journal:  CMAJ       Date:  2005-09-27       Impact factor: 8.262

5.  Effects of ursodeoxycholic acid and/or low-calorie diet on steatohepatitis in rats with obesity and hyperlipidemia.

Authors:  Jian-Gao Fan; Lan Zhong; Li-Yan Tia; Zheng-Jie Xu; Min-Sheng Li; Guo-Liang Wang
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 6.  Identification and treatment of metabolic complications in pediatric obesity.

Authors:  Katie Larson Ode; Brigitte I Frohnert; Brandon M Nathan
Journal:  Rev Endocr Metab Disord       Date:  2009-09       Impact factor: 6.514

Review 7.  Clinical advances in pediatric nonalcoholic fatty liver disease.

Authors:  Jeffrey B Schwimmer
Journal:  Hepatology       Date:  2016-03-04       Impact factor: 17.425

8.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 9.  Nonalcoholic steatohepatitis in children.

Authors:  Eve A Roberts
Journal:  Curr Gastroenterol Rep       Date:  2003-06

Review 10.  The metabolic syndrome and nonalcoholic fatty liver disease in children.

Authors:  Shikha S Sundaram; Phil Zeitler; Kristen Nadeau
Journal:  Curr Opin Pediatr       Date:  2009-08       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.